Der Klinikarzt 2012; 41(10): 464-469
DOI: 10.1055/s-0032-1330947
Schwerpunkt
© Georg Thieme Verlag Stuttgart · New York

Schilddrüsenkarzinom – Individualisierte chirurgische Konzepte

Thyroid cancer – An individualized surgical concept
Thomas J Musholt
1   Sektion endokrine Chirurgie, Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Universitätsmedizin Mainz
› Author Affiliations
Further Information

Publication History

Publication Date:
07 November 2012 (online)

In der Bundesrepublik Deutschland werden etwa 5,3 Mio. Männer und 9,0 Mio. Frauen (gesamt etwa 14,3 Mio.) aufgrund einer Erkrankung der Schilddrüse ärztlich behandelt. Die Schilddrüsenoperation stellt einen der häufigsten viszeralchirurgischen Eingriffe dar [1]. Hierbei handelt es sich überwiegend um Eingriffe bei benignen Erkrankungen der Schilddrüse während nur etwa 5000–10 000 Neuerkrankungen eines Schilddrüsenkarzinoms pro Jahr diagnostiziert werden.

In Germany about 5,3 million men and 9,0 million women (altogether about 14,3 million) are receiving medical treatment due to diseases of the thyroid gland. Operations on the thyroid gland constitute one of the most frequent procedures in visceral surgery. Most interventions are for benign diseases of the thyroid gland in comparison to the merely around 5000 to 10 000 newly diagnosed thyroid cancers per year.

 
  • Literatur

  • 1 Musholt TJ. Total thyroidectomy for multinodular goiter. Chirurg 2010; 81: 608-611
  • 2 DeLellis RA. International Agency for Research on Cancer, World Health Organization, International Academy of Pathology, International Association for the Study of Lung Cancer. Pathology and genetics of tumours of endocrine organs. Lyon: IARC Press; 2004. 320.
  • 3 Musholt TJ, Clerici T, Dralle H et al. German Association of Endocrine Surgeons practice guidelines for the surgical treatment of benign thyroid disease. Langenbecks Arch Surg 2011; 396: 639-649
  • 4 Musholt TJ, Fottner C, Weber MM et al. Detection of papillary thyroid carcinoma by analysis of BRAF and RET/PTC1 mutations in fine-needle aspiration biopsies of thyroid nodules. World J Surg 2010; 34: 2595-2603
  • 5 Musholt TJ, Schonefeld S, Schwarz CH et al. Impact of pathognomonic genetic alterations on the prognosis of papillary thyroid carcinoma. ESES vienna presentation. Langenbecks Arch Surg 2010; 395: 877-883
  • 6 Kim TH, Park YJ, Lim JA et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 2012; 118: 1764-1773
  • 7 Kloos RT, Eng C, Evans DB et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009; 19: 565-612
  • 8 Cooper DS, Doherty GM, Haugen BR et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006; 16: 109-142
  • 9 Cooper DS, Doherty GM, Haugen BR et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-1214
  • 10 Pacini F, Schlumberger M, Dralle H et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154: 787-803
  • 11 Ferlito A, Robbins KT, Silver CE, Hasegawa Y, Rinaldo A. Classification of neck dissections: an evolving system. Auris Nasus Larynx 2009; 36: 127-134
  • 12 Sobin LH, Gospodarowicz MK, Wittekind C. International Union against Cancer. TNM classification of malignant tumours. 7th ed. Chichester, West Sussex, UK ; Hoboken, NJ: Wiley-Blackwell; 2010
  • 13 Dralle H, Damm I, Scheumann GF et al. Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma. Surg Today 1994; 24: 112-121
  • 14 Carty SE, Cooper DS, Doherty GM et al. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid: official journal of the American Thyroid Association 2009; 19: 1153-1158
  • 15 Carling T, Carty SE, Ciarleglio MM et al. American Thyroid Association design and feasibility of a prospective randomized controlled trial of prophylactic central lymph node dissection for papillary thyroid carcinoma. Thyroid: official journal of the American Thyroid Association 2012; 22: 237-244
  • 16 Brauckhoff M, Machens A, Thanh PN et al. Impact of extent of resection for thyroid cancer invading the aerodigestive tract on surgical morbidity, local recurrence, and cancer-specific survival. Surgery 2010; 148: 1257-1266
  • 17 Musholt TJ, Musholt PB, Behrend M, Raab R, Scheumann GF, Klempnauer J. Invasive differentiated thyroid carcinoma: tracheal resection and reconstruction procedures in the hands of the endocrine surgeon. Surgery discussion 1999; 126: 1087-1087
  • 18 Volante M, Papotti M. Poorly differentiated thyroid carcinoma: 5 years after the 2004 WHO classification of endocrine tumours. Endocr Pathol 2010; 21: 1-6
  • 19 Machens A, Dralle H. Prophylactic thyroidectomy in RET carriers at risk for hereditary medullary thyroid cancer. Thyroid 2009; 19: 551-554
  • 20 Machens A, Dralle H. Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab 2010; 95: 2655-2663
  • 21 Karges W, Dralle H, Raue F et al. Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter: German evidence-based consensus recommendation. Exp Clin Endocrinol Diabetes 2004; 112: 52-58
  • 22 Scollo C, Baudin E, Travagli JP et al. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2003; 88: 2070-2075
  • 23 Machens A, Dralle H. Prognostic Impact of N Staging in 715 Medullary Thyroid Cancer Patients: Proposal for a Revised Staging System. Ann Surg 2012;